Bayer AG (BAYZF)
50.56
-0.38
(-0.74%)
USD |
OTCM |
Oct 27, 16:00
Bayer Enterprise Value : 88.84B for Oct. 27, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 27, 2026 | 88.84B |
| October 26, 2026 | 89.21B |
| October 23, 2026 | 87.69B |
| October 22, 2026 | 87.69B |
| October 21, 2026 | 87.69B |
| October 20, 2026 | 87.69B |
| October 19, 2026 | 87.12B |
| October 16, 2026 | 88.00B |
| October 15, 2026 | 88.28B |
| October 14, 2026 | 87.34B |
| October 13, 2026 | 87.34B |
| October 12, 2026 | 87.16B |
| October 09, 2026 | 87.37B |
| October 08, 2026 | 86.33B |
| October 07, 2026 | 88.82B |
| October 06, 2026 | 88.82B |
| October 05, 2026 | 87.79B |
| October 02, 2026 | 91.04B |
| October 01, 2026 | 88.33B |
| September 30, 2026 | 93.38B |
| September 29, 2026 | 93.55B |
| September 28, 2026 | 95.76B |
| September 25, 2026 | 94.85B |
| September 24, 2026 | 94.46B |
| September 23, 2026 | 94.95B |
| Date | Value |
|---|---|
| September 22, 2026 | 94.79B |
| September 21, 2026 | 94.32B |
| September 18, 2026 | 93.21B |
| September 17, 2026 | 94.57B |
| September 16, 2026 | 94.57B |
| September 15, 2026 | 95.60B |
| September 14, 2026 | 95.60B |
| September 11, 2026 | 94.68B |
| September 10, 2026 | 94.68B |
| September 09, 2026 | 94.68B |
| September 08, 2026 | 94.68B |
| September 04, 2026 | 94.68B |
| September 03, 2026 | 94.75B |
| September 02, 2026 | 94.75B |
| September 01, 2026 | 94.75B |
| August 31, 2026 | 94.53B |
| August 28, 2026 | 94.53B |
| August 27, 2026 | 94.53B |
| August 26, 2026 | 95.52B |
| August 25, 2026 | 95.52B |
| August 24, 2026 | 94.36B |
| August 21, 2026 | 94.14B |
| August 20, 2026 | 94.61B |
| August 19, 2026 | 92.83B |
| August 18, 2026 | 92.83B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Merck KGaA | 32.80B |
| Breakthrough Chemistry, Inc. | 0.241M |
| Cardiac Biotech Solutions, Inc. | 5.690M |
| Fresenius SE & Co. KGaA | 41.25B |
| Carl Zeiss Meditec AG | 3.520B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 266.26M |
| Revenue (Quarterly) | 12.64B |
| Total Expenses (Quarterly) | 12.39B |
| EPS Diluted (Quarterly) | 0.2592 |
| Gross Profit Margin (Quarterly) | 58.24% |
| Profit Margin (Quarterly) | 2.11% |
| Earnings Yield | -4.05% |
| Operating Earnings Yield | 14.72% |
| Normalized Earnings Yield | 3.908 |